instruction:
Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.
question:
Paragraph: "The sight of the moon’s shadow passing directly in front of the sun, blotting out all but the halo-like solar corona, may draw the largest live audience for a celestial event in human history. When those watching via broadcast and online media are factored into the mix, the spectacle will likely smash records. “It will certainly be the most observed total eclipse in history,” astronomer Rick Fienberg of the American Astronomical Society (AAS) said last week. The eclipse begins its cross-country trajectory over the Pacific Coast of Oregon in late morning. It will reach South Carolina’s Atlantic shore some 90 minutes later. The total eclipse of the sun is considered one of the most spell-binding phenomena in nature but it rarely occurs over a wide swath of land, let alone one of the world’s most heavily populated countries at the height of summer. In terms of audience potential, it is hard to top the United States, with its mobile and affluent population, even though the direct path is mostly over rural areas, towns and small cities. The largest is Nashville, Tennessee, a city of 660,000 residents. Even so the advent of social media and inexpensive high-tech optics have boosted public awareness, assuring what many U.S. experts predict will be unprecedented viewership for the so-called “Great American Eclipse.”   Some might take issue with that prediction, citing a solar eclipse visible over parts of India, Nepal, Bangladesh and central China in July 2009. National Geographic estimated 30 million people in Shanghai and Hangzhou alone were in its path that day. On Monday, the deepest part of the shadow, or umbra, cast by the moon will fall over a 70-mile-wide (113-km-wide), 2,500-mile-long (4,000-km-long) ""path of totality"" traversing 14 states. The 12 million people who live there can view the eclipse at its fullest merely by walking outside and looking up, weather permitting. (tmsnrt.rs/2fNQHFb)  LIVESTREAMING AND PRICE-GOUGING  Some 200 million Americans reside within a day’s drive of the totality zone, and as many as 7 million, experts say, are expected to converge on towns and campgrounds along the narrow corridor for the event. Many are attending multiday festivals featuring music, yoga and astronomy lectures. Millions more could potentially watch in real time as the eclipse is captured by video cameras mounted on 50 high-altitude balloons and streamed online in a joint project between NASA and Montana State University. A partial eclipse will appear throughout North America. Adding further to the excitement is the wide availability of affordable solar-safe sunglasses produced by the millions and selling so fast that suppliers were running out of stock. The owner of one leading manufacturer reported price gouging by second-hand dealers who were buying up large supplies and reselling them over the internet at a huge mark-up. Not all the hoopla will unfold on dry land. Welsh pop singer Bonnie Tyler is slated to perform her 1983s hit single “Total Eclipse of the Heart” aboard a cruise liner as the vessel sails into the path of totality from Florida on Monday. Back on the ground, forest rangers, police and city managers in the total eclipse zone are bracing for a crush of travelers they fear will cause epic traffic jams and heighten wildfire hazards. “Imagine 20 Woodstock festivals occurring simultaneously across the nation,” Michael Zeiler, an AAS advisory panel member wrote on his website, GreatAmericanEclipse.com, referring to the famously chaotic 1969 outdoor rock extravaganza in upstate New York. Hundreds of residents in a prime-viewing area in Oregon had to evacuate on Saturday under threat from a wildfire raging in the Deschutes National Forest, according to InciWeb fire-tracking website. The so-called Milli Fire, which has scorched more than 7,8OO acres (3,162 hectare), is one of seven burning in Oregon, Montana and Idaho, three of the states crossed by the totality path. Zeiler, an avowed “eclipse chaser” who made the 650-mile (1,046-km) drive from his New Mexico home to Wyoming for a choice view, said South Carolina is likely to see the greatest influx as the destination state closest to the entire U.S. Eastern seaboard. Monday’s event will be the first total solar eclipse spanning the entire continental United States since 1918 and the first visible anywhere in the Lower 48 states in 38 years. The next one over North America is due in just seven years, in April 2024." Claim: Millions of Americans to gaze upon Monday's once-in-a-lifetime eclipse.
answer:
Twilight will fall at midday on Monday, stars will glimmer and birds will roost in an eerie stillness as millions of Americans and visitors witness the first total solar eclipse to traverse the United States from coast to coast in 99 years.


question:
Paragraph: The analysis suggests the potentially harmful effect of Celebrex dosage is most pronounced in higher-risk patients, researchers said at the American College of Cardiology scientific meeting. “Patients at low cardiovascular risk should take some level of comfort,” said Dr. Scott Solomon, lead researcher of the National Cancer Institute-sponsored analysis. “That wasn’t so clear previously.”   Doctors should exercise caution in prescribing the drug, generally known as celecoxib, in high-risk patients, said Solomon, whose analysis was also published online in the journal Circulation. Celebrex belongs to a class of pain drugs known as cox-2 inhibitors and is the only such drug still on the market in the United States. Merck and Co Inc withdrew its widely used cox-2 drug, Vioxx, from the market in 2004 after a study showed it doubled the risk of heart attack and stroke in long- term users. Another cox-2 inhibitor from Pfizer called Bextra was also pulled from the U.S. market due to safety concerns. While the analysis sheds light on how the drug should be used, Solomon said he could not judge whether the data lift the cloud over this class of drugs. The six trials involving a total of 7,950 patients all studied Celebrex against a placebo for uses other than arthritis. Patients received either 400 milligrams once a day, 200 mg twice a day, or 400 mg twice a day. The primary goal of the pooled analysis was an assessment of the combined risk of cardiovascular death, heart attack, stroke, heart failure or events involving blood clots. Researchers found the heart risk was lowest at the 400 mg daily dose. They found nearly a two-fold risk of adverse heart events with the 200 mg twice daily dose and that jumped to about a three-fold risk at the 400 mg twice daily dose. “Even 400 mg once a day showed elevated risk” in the high-risk population, Solomon said, adding he could not extrapolate whether doses lower than 400 mg cut risk further. The increased risk was not affected by aspirin use, researchers said. “Most of the data used in this pooled analysis have previously been published and are consistent with what we already know about the cardiovascular risks of Celebrex and other prescription arthritis pain relievers,” said Gail Cawkwell, Pfizer’s executive medical director. “The analysis doesn’t provide any new conclusions on the FDA-approved doses of Celebrex, including the most commonly prescribed dose of 200 mg daily,” she said. Dr. Steven Nissen of the Cleveland Clinic, who has a study on lower doses underway, added: “There aren’t long-term randomized placebo-controlled trials for that dose, The only way we’re ever going to answer these questions is with good randomized prospective data,” he said. “We’ll tell it like it is when the data is in.” Claim: Celebrex risky in high-risk patients, study finds.
answer:
Doctors should prescribe the lowest doses of Celebrex possible in patients at high risk of heart problems, researchers who did a combined analysis of six studies of the Pfizer Inc pain drug said on Monday.


question:
Paragraph: Although this therapy is not yet available for patient use, the story makes a point of noting that the cost may well be “stratospheric,” should it make it to market. If approved, such treatments are expected to command stratospheric prices. For example, a separate Spark gene therapy for a rare type of childhood blindness, which is on track for Food and Drug Administration clearance soon, could cost $1 million per patient for infusions in both eyes, according to some Wall Street analysts. Still, the therapies can produce at least some offsetting savings. Porteus noted in his editorial that the hemophilia therapy resulted in savings of about $200,000 a year per patient because of the elimination of clotting-factor infusions. The story summarizes the outcome of the small, 10-person trial that dominates this narrative: Lindsey George, the lead investigator and a hematologist at Children’s Hospital of Philadelphia, said that nine of the 10 men in the trial didn’t experience any bleeding episodes after the gene therapy treatment. The one patient who needed clotting factor because of bleeding used 91 percent less than before, she said. Although the story does not address harms directly–and should have–it does note that one of the worrying side effects of gene therapy—spurring the body to attack itself—was not present in this study. It is clear from the story that the study is small and an “early-stage trial.” One source also notes that the researchers tracked individuals in the study for no more than a year and a half, making longer term assessments unavailable. The story could have done more, though, to signal to the reader that, despite the encouraging outcomes of the study, the treatment is still very much under development. The next stage—Phase 3 trials—requires more participants, more careful study design, and takes, on average, three years to complete. The treatment described here, if ultimately proved worthy, could have a profound impact on a serious genetic condition. Independent sources are identified in the story, as are the funders. But missing from the text is information describing linkages between the two funders—Spark Therapeutics and Pfizer—and the lead researchers. It’s not clear from the story that there is a financial relationship. Individuals coping with hemophilia B have few options, and the story describes the main one: injections of blood-clotting factor to stem runaway bleeding. Since the story notes that the research is at an early stage with only 10 participants, a reader can easily infer that the treatment is not yet available. However, additional information about remaining evaluation stages for this treatment would have been a useful reinforcing addition. Hemophilia B sufferers who see this story will likely be contacting their doctors. The story establishes novelty with this: The researchers presented earlier findings on the gene therapy a year ago at the American Society of Hematology’s annual meeting, but the latest data covers a larger patient group and a longer time period. A news release issued by Children’s Hospital of Philadelphia did a good job of describing this study; the Post story could have picked up more of the salient details from that text but reveals independent reporting nevertheless by including sources not connected to the study. Claim: Gene therapy makes a big advance treating hemophilia B blood disorder
answer:

iStock / Getty Images Plus A small, early-stage study published in the New England Journal of Medicine found that a single intravenous infusion of a novel bioengineered gene therapy treatment helped spare nine of 10 hemophilia B sufferers from repeated injections of blood-clotting factor to prevent debilitating bleeding episodes. This well-written story shares that information carefully and clearly. However, more details about the years-long road ahead for this treatment’s development and about possible ties between the researchers and the funders would have made the piece stronger. Complicating the care taken by the reporter, however, is a glaring headline that promises much more than this small study can deliver (“Gene therapy makes a big advance treating hemophilia B blood disorder”). Whether this particular treatment revolutionizes the landscape for hemophilia B sufferers will remain an open question for some years. People who have inherited the hemophilia B bleeding disorder face a lifetime of replacement therapy: injecting clotting factor when life deals them a stumble or a scrape. Gene therapy research appears to be on the cusp of offering an alternate treatment that would allow these individuals to lead normal lives. While it is important for journalists to track progress toward such an important goal, it is also critical that stories tread cautiously to avoid giving false hope at early stages.